Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.67 USD | +0.31% | +6.85% | -0.31% |
May. 09 | Enfusion Shares Fall Despite Higher Q1 Results | MT |
May. 09 | Transcript : Enfusion, Inc., Q1 2024 Earnings Call, May 09, 2024 |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 62% by 2026.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 127.12 times its estimated earnings per share for the ongoing year.
- With an enterprise value anticipated at 4.06 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Sector: Software
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-0.31% | 889M | - | ||
+11.75% | 3,123B | C+ | ||
+10.06% | 86.45B | B | ||
+6.04% | 78.6B | B+ | ||
-14.66% | 53.98B | B+ | ||
+26.73% | 48.46B | D+ | ||
-24.44% | 46.78B | B- | ||
+31.74% | 46.36B | D+ | ||
+82.12% | 42.36B | D+ | ||
-8.15% | 25.25B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ENFN Stock
- Ratings Enfusion, Inc.